LRRC32 抗体 (PE-Cy7)
Quick Overview for LRRC32 抗体 (PE-Cy7) (ABIN2659350)
抗原
See all LRRC32 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
纯化方法
- The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.
-
亚型
- IgG2b kappa
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
缓冲液
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
注意事项
- Protect from prolonged exposure to light. Do not freeze.
-
储存条件
- 4 °C
-
储存方法
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
-
- LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))
-
别名
- GARP
-
背景
- Glycoprotein A Repetitions Predominant (GARP), also known as leucine rich repeat containing 32 (LRC32), is a 80 kD type I membrane glycoprotein with 20 leucine rich repeats in the extracellular portion of the protein. GARP was found on the surface of megakaryocytes, platelets, and activated Tregs (CD4+, CD25+, FoxP3+ cells) and serves as a receptor for latent TGF-β. Recent evidence suggests that GARP may play a role in controlling suppressor function of Tregs. A mutation in GARP has been reported in a large Samaritan kindred with Usher syndrome type 1, an autosomal recessive disease characterized by profound congenital sensorineural deafness, vestibular dysfunction, and progressive visual loss. In addition, it has been found that GARP mRNA is highly amplified in different tumors, which indicates that tumor cells may use GARP to express TGF-β or to capture TGF-β from their surroundings, resulting in local suppression of anti-tumor immune responses or the induction of Tregs.
-
途径
- Activated T Cell Proliferation
抗原
-